Profil bibliographique

Tania Nikolcheva

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

50Publications signalées

2618Citations signalées

1Affiliations récentes

Institutions déclarées

Domaines associés

Parkinson's Disease Mechanisms and TreatmentsNeurological disorders and treatmentsAlzheimer's disease research and treatmentsNuclear Receptors and SignalingHealth Systems, Economic Evaluations, Quality of Life

Publications récentes

Accès ouvert 2026 preprintOpenAlex

Satisfaction with long-term remote monitoring with digital health technologies: relationships with adherence and disease metrics in two clinical trials in people living with early-stage Parkinson's (Preprint)

Bernhard Fehlmann, Alessandra Elena Thomann, Stefan Lambrecht, Evan Davies et autres

0 citations

2026 articleOpenAlex

Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study

Tania Nikolcheva, Gennaro Pagano, Judith Anzures-Cabrera, Dylan Trundell et autres

4 citationsThe Lancet

Accès ouvert 2026 preprintOpenAlex

PADOVA: A Phase IIb, Multicentre, Randomised, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Individuals with Early-Stage Parkinson Disease on Stable Symptomatic Monotherapy

Tania Nikolcheva, Gennaro Pagano, J Anzures-Cabrera, Dylan Trundell et autres

0 citationsSSRN Electronic Journal

Accès ouvert 2025 erratumOpenAlex

Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson’s disease trials

Gennaro Pagano, Dylan Trundell, Tanya Simuni, Nicola Pavese et autres

0 citationsnpj Parkinson s Disease

Accès ouvert 2025 articleOpenAlex

Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson’s disease trials

Gennaro Pagano, Dylan Trundell, Tanya Simuni, Nicola Pavese et autres

2 citationsnpj Parkinson s Disease

Accès ouvert 2025 articleOpenAlex

Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab

Kirsten I. Taylor, Florian Lipsmeier, Marzia A. Scelsi, Ekaterina Volkova-Volkmar et autres

14 citationsnpj Digital Medicine

Accès ouvert 2025 articleOpenAlex

Estimation of and clinical consensus on the meaningful motor progression threshold on MDS-UPDRS Part III

Dylan Trundell, Evan Davies, Louise Barrett, Stefano Zanigni et autres

6 citationsJournal of Parkinson s Disease

Accès ouvert 2024 articleOpenAlex

A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data

Tania Nikolcheva, Gennaro Pagano, Nathalie Pross, Tanya Simuni et autres

16 citationsParkinsonism & Related Disorders

Accès ouvert 2024 articleOpenAlex

Biologically defined neuronal synuclein disease as a tool to advance drug development

Gennaro Pagano, Tien Dam, Geoffrey A. Kerchner, Wendy R. Galpern et autres

3 citationsnpj Parkinson s Disease

Accès ouvert 2024 articleOpenAlex

Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial

Gennaro Pagano, Annabelle Monnet, Benjamin Ribba, Hanno Svoboda et autres

58 citationsNature Medicine

Accès ouvert 2024 articleOpenAlex

Modeling of Parkinson’s Disease Progression and Implications for Detection of Disease Modification in Treatment Trials

Benjamin Ribba, Tanya Simuni, Kenneth Marek, Andrew Siderowf et autres

16 citationsJournal of Parkinson s Disease

2024 articleOpenAlex

Exploratory Analysis of PASADENA Open-label Extension Evaluating the Effect of Prasinezumab on the Progression of Motor Signs and Symptoms (S30.006)

Gennaro Pagano, Annabelle Monnet, Tanya Simuni, Ronald B. Postuma et autres

1 citationNeurology

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.